Chronic porcine two-hit model with hemorrhagic shock and Pseudomonas aeruginosa sepsis

被引:9
作者
Eissner, B [1 ]
Matz, K [1 ]
Smorodchenko, A [1 ]
Röschmann, A [1 ]
Von Specht, BU [1 ]
机构
[1] Univ Freiburg, Dept Surg, D-7800 Freiburg, Germany
关键词
two-hit model; sepsis; hemorrhagic shock; Pseudomonas aeruginosa; pig;
D O I
10.1159/000048889
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Sepsis is still a major cause of death despite well-developed therapeutical strategies such as antibiotics and supportive medication. The aim of this study was to characterize the long-term effects of a two-hit porcine sepsis model with a hemorrhagic shock as 'first hit' followed by a Pseudomonas aeruginosa infusion as 'second hit'. Materials and Methods: Twelve juvenile healthy pigs were anesthetized and hemodynamically monitored. The two-hit group (n = 6) underwent a hemorrhagic shock with a 50% reduction of the mean arterial pressure and/or cardiac index for 45 min, followed by resuscitation, while the control group (n = 6) received no pretreatment. All chronically catheterized conscious pigs were challenged with a P. aeruginosa infusion (1.6 x 10(7) CFU/kg/h for the first 24 IT followed by 1.6 x 106 CFU/kg/h for the next 24 h) and observed for another 48 h. Results: The two-hit group showed the following significant differences to the control group: higher APACHE II scores prior to sepsis induction, increased persisting mean pulmonary arterial pressure (MPAP) and pulmonary vascular resistance index (PVRI) during bacterial challenge. In contrast, systemic vascular resistance (SVRO was reduced at the end of the study. Throughout the observation period, the mean arterial pressure (MAP) was significantly reduced. Conclusions: The present study shows that the clinical course and hemodynamic effects of a P. aeruginosa sepsis will be aggravated by a preceding hemorrhagic shock during an observation period of 96 h. This two-hit model represents a valid, clinically relevant experimental protocol in sepsis research. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 25 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   CONTRIBUTION OF TUMOR NECROSIS FACTOR-A TO PULMONARY CYTOKINE EXPRESSION AND LUNG INJURY AFTER HEMORRHAGE AND RESUSCITATION [J].
ABRAHAM, E ;
JESMOK, G ;
TUDER, R ;
ALLBEE, J ;
CHANG, YH .
CRITICAL CARE MEDICINE, 1995, 23 (08) :1319-1326
[3]   E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial [J].
Angus, DC ;
Birmingham, MC ;
Balk, RA ;
Scannon, PJ ;
Collins, D ;
Kruse, JA ;
Graham, DR ;
Dedhia, HV ;
Homann, S ;
MacIntyre, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1723-1730
[4]  
AYALA A, 1990, ARCH SURG-CHICAGO, V125, P70
[5]   A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL [J].
BONE, RC ;
BALK, RA ;
FEIN, AM ;
PERL, TM ;
WENZEL, RP ;
REINES, HD ;
QUENZER, RW ;
IBERTI, TJ ;
MACINTYRE, N ;
SCHEIN, RMH ;
TRENHOLME, G ;
NIEDERMAN, M ;
CHALFIN, D ;
ABALOS, A ;
OROPELLO, J ;
EMPSON, P ;
CAMINITII, S ;
GREENMAN, R ;
BOOTH, F ;
PLOUFFE, J ;
RUSSELL, J ;
GIANAKOPOULOS, G ;
IANNINI, P ;
HINDES, R ;
COBLENS, K ;
KOHLER, R ;
MARTIN, M ;
BERNARD, G ;
EDWARDS, J ;
CRISLIP, M ;
FILLER, S ;
NASRAWAY, SA ;
SIGEL, PK ;
SOTTILE, FD ;
MARTIN, DH ;
DEBOISBLANC, BP ;
CHANDRASEKAR, PH ;
BROUGHTON, WA ;
MIDDLETON, RM ;
SEIBERT, AF ;
EMMANUEL, G ;
LIE, TH ;
ANDERSON, CLV ;
PANKEY, GA ;
ANDERSON, P ;
OLSEN, K ;
SANPEDRO, GS ;
GRAHAM, D ;
GROSSMAN, J ;
WELS, PB .
CRITICAL CARE MEDICINE, 1995, 23 (06) :994-1006
[6]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[7]   DOES BLOOD-TRANSFUSION OR HEMORRHAGIC-SHOCK INDUCE IMMUNOSUPPRESSION [J].
CUE, JI ;
PEYTON, JC ;
MALANGONI, MA .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1992, 32 (05) :613-617
[8]   Animal models of sepsis and shock: A review and lessons learned [J].
Deitch, EA .
SHOCK, 1998, 9 (01) :1-11
[9]  
Dellinger RP, 1997, CHEST, V111, P744
[10]  
ERTEL W, 1991, SURGERY, V110, P440